Otsuka-Click alliance on digital therapeutics to help MDD patients
Category: #health  By Saipriya Iyer  Date: 2019-01-04
  • share
  • Twitter
  • Facebook
  • LinkedIn

Otsuka-Click alliance on digital therapeutics to help MDD patients

Otsuka America, Inc., and Click Therapeutics, Inc., have reportedly announced that they have signed an agreement to develop and commercialize a digital therapeutic for the treatment of MDD. The partnership aims to provide medical assistance to MDD patients, the needs of whom remain unmet, and improve their mental health condition.

Reportedly, this collaboration will leverage Click’s potential to discover and validate a software application for commercial deployment, with the help of Otsuka’s expertise in developing prescription therapies for patients afflicted with serious mental illnesses. Apparently, both the companies believe that digital therapeutics align with psychiatry naturally, and have the capability to transform mental healthcare. By working together, both the companies intend to bring a new offering to the market that will provide a novel treatment for patients with Major Depressive Disorder (MDD).

Reliable sources state that Otsuka has agreed to fund the development of Click’s novel mobile application ‘CT-152’ for Major Depressive Disorder, and commercialize the same worldwide after obtaining regulatory approvals. Otsuka will pay $10 million upfront in regulatory milestone payments, and $20 million in development funding. Additionally, Otsuka will pay $272 million in commercial milestone payments based on regulatory approvals. Click will also receive royalties based on global sales of the software and the digital therapeutic applications.

Kabir Nath, President & CEO, Otsuka North America Pharmaceutical Business Division, Otsuka America, was reportedly quoted stating that this collaboration signifies Otsuka’s commitment to meet medical needs of the patients by developing innovative solutions beyond conventional medication. The firm’s goal is to provide evidence-driven cognitive therapies to a wide range of patients who are undergoing MDD, amid the challenges of a shortage of mental health professionals and less time to conduct cognitive therapy.

Nath added that the company is proud to be one of the few pharmaceutical firms that invests in developing medicinal and digital products for treating mental disorders. Otsuka is breaking barriers, he says, collaborating with top notch therapeutic technology firms like Click that have a similar vision as its own.



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Triple Gene releases Phase 1 study data for INXN-4001 in heart failure
Triple Gene releases Phase 1 study data for INXN-4001 in heart failure
By Saipriya Iyer

Triple Gene LLC- a U.S. based cardiovascular gene therapy enterprise recently furnished preliminary data from its Phase 1 trial of INXN-4001, an investigational therapeutic candidate used in the treatment of cardiac fa...

Alibaba plans to offer bitcoin rewards to shoppers through Lolli
Alibaba plans to offer bitcoin rewards to shoppers through Lolli
By Saipriya Iyer

 

  • Now Alibaba shoppers can earn free bitcoin when they purchase products on Alibaba's e-commerce platform
  • Reportedly, the partnership would enable shoppers...

Daiichi Sankyo announces positive results from Phase 3 pivotal trial
Daiichi Sankyo announces positive results from Phase 3 pivotal trial
By Saipriya Iyer

Daiichi Sankyo Company, Limited (hereafter Daiichi Sankyo), today made a breakthrough announcement stating that the main objective has been achieved from ESAX-DN—a phase 3 pivotal study of esaxerenone—a pro...